Category: HCRU

HCRU

Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database

Post author By Kostikas K, Price D, Gutzwiller F S, Jones B I, Loefroth E, Clemens A, Fogel R, Jones R and Cao H
Post date 18 July 2020

Kostikas K, Price D, Gutzwiller F S, Jones B I, Loefroth E, Clemens A, Fogel R, Jones R, Cao H. 18 Jul 2020

Epilepsy & Behaviour HCRU

Healthcare utilization and associated costs following initiation of perampanel in patients with epilepsy

Post author By Morgan C L, Varga S, Tsong W, Jenkins-Jones S and Holden S E
Post date 28 May 2020

Morgan C L, Varga S, Tsong W, Jenkins-Jones S, Holden S E. 28 May 2020

Diabetes Obesity & Metabolism HCRU

Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study

Post author By Holden S E, Morgan C L, Qiao Q, Jenkins-Jones S, Berni E R and Currie C J
Post date 20 February 2017

Holden S E, Morgan C L, Qiao Q, Jenkins-Jones S, Berni E R, Currie C J. 20 Feb 2017

HCRU

Healthcare Resource Utilisation Associated with Patients Treated with Either Exenatide Once Weekly or Basal Insulin: A Retrospective UK Database Analysis

Post author By Qiao Q, Morgan C L, Jenkins-Jones S, Berni E R, Currie C J and Holden S E
Post date 1 November 2016

Qiao Q, Morgan C L, Jenkins-Jones S, Berni E R, Currie C J and Holden S E. 01 Nov 2016

HCRU

Evaluation of The Cost Effectiveness of Rifaximin-α 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In Sweden

Post author By Poole C D, Berni E R, Conway P, Radwan A and Currie C J
Post date 1 November 2016

Poole C D, Berni E R, Conway P, Radwan A, Currie C J. 01 Nov 2016

HCRU

Cost Effectiveness of Rifaximin-α 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In United Kingdom

Post author By Berni E R, Poole C D, Conway P, Radwan A and Currie C J
Post date 1 November 2016

Berni E R, Poole C D, Conway P, Radwan A, Currie C J. 01 Nov 2016

HCRU

Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe

Post author By Holden S E, Currie C J, Lennon M, Reynolds A V and Moots R J
Post date 9 May 2016

Holden S E, Currie C J, Lennon M, Reynolds A V, Moots R J. 09 May 2016

HCRU Hepatic Encephalopathy

The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α

Orr J G, Currie C J, Berni E R, Goel A, Moriarty K J, Sinha A, Gordon F, Dethier A, Dillon J F, Clark K, Richardson P, Middleton P, Patel V, Shawcross D, Preedy H, Aspinall R J, Hudson M. 07 Mar 2016

HCRU Value in Health

Evaluation of The Cost Effectiveness and Societal Impact of Rifaximin-α 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In The Netherlands

Post author By Whitehouse J, Berni E R, Conway P, Radwan A, Henrar R and Currie C J
Post date 1 November 2015

Whitehouse J T, Berni E R, Conway P, Radwan A, Henrar R, Currie C J. 01 Nov 2015

Transforming real-world data into transparent, reliable, and reliable real-world evidence

44 (0) 2920 782856

enquiries@humandatasciences.com

24 Wordsworth Avenue, Cardiff, CF24 3FR United Kingdom

Copyright Pharmatelligence Limited (trading as Human Data Sciences) is a Private Limited Company (PLC) registered in England and Wales with Company Number 7107514.

Livingstone® is a Trusted Research Environment (TRE)

Quick Links

Quick Links

Transforming real-world data into transparent, reliable, and replicable real-world evidence

44 (0) 2920 782856

instantRWE@humandatasciences.com

The Global Pharma Research Centre,
24 Wordsworth Avenue, Cardiff, CF24 3FR United Kingdom

Copyright Pharmatelligence Limited (trading as Human Data Sciences) is a Private Limited Company (PLC) registered in England and Wales with Company Number 7107514.

Livingstone^® is a Trusted Research Environment (TRE)

Web Design – Create Summit

Copyright^© Human Data Sciences – All rights reserved

Site by Create Summit

Copyright © Human Data Sciences – All rights reserved